Development of the Angioedema Control Test (AECT) ‐ a patient reported outcome measure that assesses disease control in patients with recurrent angioedema,Allergy

当前位置： X-MOL 学术 › Allergy › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Development of the Angioedema Control Test (AECT) ‐ a patient reported outcome measure that assesses disease control in patients with recurrent angioedema
Allergy ( IF 12.6 ) Pub Date : 2020-03-06 , DOI: 10.1111/all.14144
Karsten Weller ₁ , Tamara Donoso ₁ , Markus Magerl ₁ , Emel Aygören-Pürsün ₂ , Petra Staubach ₃ , Inmaculada Martinez-Saguer ₄ , Tomasz Hawro ₁ , Sabine Altrichter ₁ , Karoline Krause ₁ , Frank Siebenhaar ₁ , Martin Metz ₁ , Torsten Zuberbier ₁ , Denise Freier ₁ , Marcus Maurer ₁

Affiliation

Recurrent angioedema (AE) is an important clinical problem in the context of chronic urticaria (mast cell mediator–induced), ACE‐inhibitor intake and hereditary angioedema (both bradykinin‐mediated). To help patients obtain control of their recurrent AE is a major treatment goal. However, a tool to assess control of recurrent AE is not yet available. This prompted us to develop such a tool, the Angioedema Control Test (AECT).

中文翻译：

血管性水肿控制测试 (AECT) 的发展 - 一项患者报告的结果测量，用于评估复发性血管性水肿患者的疾病控制

复发性血管性水肿 (AE) 是慢性荨麻疹（肥大细胞介导的）、ACE 抑制剂摄入和遗传性血管性水肿（缓激肽介导的）背景下的一个重要临床问题。帮助患者控制复发性 AE 是主要的治疗目标。然而，尚无评估复发性 AE 控制的工具。这促使我们开发了这样一种工具，即血管性水肿控制测试 (AECT)。

更新日期：2020-03-06

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11